Literature DB >> 6977549

Vitamin D metabolites and parathyroid hormone in Cushing's syndrome: relationship to calcium and phosphorus homeostasis.

J W Findling, N D Adams, J Lemann, R W Gray, C J Thomas, J B Tyrrell.   

Abstract

We studied the effects of glucocorticoid excess on calcium and phosphorus homeostasis in relation to vitamin D metabolites and parathyroid hormone (PTH) in seven patients with spontaneous ACTH-dependent Cushing's syndrome. Remission of hypercortisolism resulted in a significant increase in tubular reabsorption of phosphate [from 76 +/- 4% to 89 +/- 2% (mean +/- SEM); P less than 0.01] and serum phosphorus (from 3.1 +/- 0.1 to 4.2 +/- 0.2 mg/dl; P less than 0.005). Serum calcium did not change, although there was a reduction in daily urinary calcium excretion from 0.23 +/- 0.02 to 0.107 +/- 0.02 mg calcium/mg creatinine. Serum immunoreactive PTH (iPTH) levels were normal during Cushing's syndrome (34 +/- 5 microleq/ml), but fell significantly after remission to 22 +/- 2 microleq/ml (P less than 0.05). This small decrease in iPTH did not correlate with the improvement of phosphate homeostasis. Plasma 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D [1,25-(OH2)D] concentrations in Cushing's syndrome did not differ from measurements in 97 normal subjects. After treatment, 25OHD did not change, but 1,25-(OH)2D fell in each patient from a mean of 44 to 22 pg/ml (P less than 0.02). 1,25-(OH)2D was inversely correlated with serum phosphorus (r = 0.59; P less than 0.01), but did not correlate with iPTH. The known impairment of intestinal calcium absorption in Cushing's syndrome cannot be attributed to a decrease in the circulating levels of 1,25-(OH)2D. Endogenous hypercortisolism decreases tubular phosphate reabsorption and serum phosphorus, increase tubular phosphate reabsorption and serum phosphorus, increases iPTH, and results in an increase in 1,25-(OH)2D. These events may contribute to the severe loss of bone mass in such patients and may account for the calciuria and phosphaturia of Cushing's syndrome.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6977549     DOI: 10.1210/jcem-54-5-1039

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  The effects of hydrocortisone, parathyroid hormone and the bisphosphonate, APD, on bone resorption in neonatal mouse calvaria.

Authors:  I R Reid; J M Katz; H K Ibbertson; D H Gray
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

2.  Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth.

Authors:  S Balsan; D Stéru; A Bourdeau; R Grimberg; G Lenoir
Journal:  Calcif Tissue Int       Date:  1987-06       Impact factor: 4.333

Review 3.  Corticosteroid-Induced osteoporosis: detection and management.

Authors:  J D Adachi; A Papaioannou
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 4.  Adrenal disorders: Is there Any role for vitamin D?

Authors:  Giacomo Tirabassi; Gianmaria Salvio; Barbara Altieri; Cristina L Ronchi; Silvia Della Casa; Alfredo Pontecorvi; Giancarlo Balercia
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

5.  Serum levels of calcitonin in Cushing's syndrome.

Authors:  G Luisetto; F Mantero; M Boscaro; L Tizian; M Zangari; D Ziliotto
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

6.  Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis.

Authors:  M J van der Veen; J W Bijlsma
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

7.  Cortisol and Phosphate Homeostasis: Cushing's Syndrome Is Associated With Reversible Hypophosphatemia.

Authors:  Ariadne Bosman; Annewieke W van den Beld; Richard A Feelders; M Carola Zillikens
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-30       Impact factor: 5.555

8.  Vitamin D Deficiency in Cushing's Disease: Before and After Its Supplementation.

Authors:  Valentina Guarnotta; Francesca Di Gaudio; Carla Giordano
Journal:  Nutrients       Date:  2022-02-25       Impact factor: 5.717

9.  Assessment of Vitamin D Metabolism in Patients with Cushing's Disease in Response to 150,000 IU Cholecalciferol Treatment.

Authors:  Alexandra Povaliaeva; Viktor Bogdanov; Ekaterina Pigarova; Artem Zhukov; Larisa Dzeranova; Zhanna Belaya; Liudmila Rozhinskaya; Galina Mel'nichenko; Natalia Mokrysheva
Journal:  Nutrients       Date:  2021-11-30       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.